WCLC Updates on the Emergence of ADCs in NSCLC
Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC).
EP: 1.WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC
Now Viewing
EP: 2.WCLC Updates on the Emergence of ADCs in NSCLC
EP: 3.WCLC Updates in Immunotherapy for NSCLC
EP: 4.WCLC Updates in Neoadjuvant Therapy for NSCLC
EP: 5.WCLC Updates in Locally Advanced NSCLC
EP: 6.WCLC Updates in Small Cell Lung Cancer
Data from the following clinical trials are discussed:
- OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
- OA03.04 - Efficacy and Safety of the Novel HER3-Directed Antibody-Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
- OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
Related Videos
Related Content
